Isabelle Niespodziany

Braine L'alleud, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Functional characterization of the antiepileptic drug candidate, padsevonil, on GABAA receptors.

Functional characterization of the antiepileptic drug candidate, padsevonil, on GABAA receptors.

Journal: Epilepsia

Published: January 15, 2020

Discovery of a small molecule modulator of the Kv1.1/Kvβ1 channel complex that reduces neuronal excitability and in vitro epileptiform activity.

Discovery of a small molecule modulator of the Kv1.1/Kvβ1 channel complex that reduces neuronal excitability and in vitro epileptiform activity.

Journal: CNS neuroscience & therapeutics

Published: June 07, 2018

A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target.

A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target.

Journal: Nature communications

Published: May 30, 2018

Intrinsic Inflammation Is a Potential Anti-Epileptogenic Target in the Organotypic Hippocampal Slice Model.

Intrinsic Inflammation Is a Potential Anti-Epileptogenic Target in the Organotypic Hippocampal Slice Model.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: February 22, 2018

Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.

Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.

Journal: Epilepsia

Published: August 10, 2017

Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na+ channel inactivation.

Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na+ channel inactivation.

Journal: Epilepsia

Published: October 07, 2016

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Journal: Epilepsia

Published: January 26, 2016

Brivaracetam augments short-term depression and slows vesicle recycling.

Brivaracetam augments short-term depression and slows vesicle recycling.

Journal: Epilepsia

Published: September 25, 2015

Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons.

Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons.

Journal: CNS neuroscience & therapeutics

Published: July 25, 2014

Loss of β1 accessory Na+ channel subunits causes failure of carbamazepine, but not of lacosamide, in blocking high-frequency firing via differential effects on persistent Na+ currents.

Loss of β1 accessory Na+ channel subunits causes failure of carbamazepine, but not of lacosamide, in blocking high-frequency firing via differential effects on persistent Na+ currents.

Journal: Epilepsia

Published: September 29, 2012

Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation.

Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation.

Journal: Journal of neuroscience research

Published: May 14, 2012

Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice.

Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice.

Journal: Journal of neuroscience research

Published: February 15, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026